Andromeda Metals has secured $3.04 million through a Share Purchase Plan and placement, aiming to advance its High Purity Alumina project and complete a Pre-feasibility study.
- Raised $3.04 million via SPP and placement
- 342 shareholders participated in the SPP
- Funds targeted for HPA Pre-feasibility study and working capital
- Shares issued at $0.0059 each
- Placement utilized ASX Listing Rule 7.1 capacity
Capital Raise Surpasses $3 Million Target
Andromeda Metals Limited (ASX:ADN) has successfully raised $3.04 million before costs through a combination of a Share Purchase Plan (SPP) and a placement of ordinary shares. The company initially targeted approximately $3 million via the SPP, but strong shareholder demand saw the total amount slightly exceed this target.
The SPP attracted participation from 342 shareholders, reflecting solid support for the company’s funding strategy. The placement component, conducted under the company’s placement capacity as per ASX Listing Rule 7.1 and Section 708 of the Corporations Act, added $102,000 at the same issue price of $0.0059 per share, bringing the total shares issued to over 17 million.
Funds Directed to High Purity Alumina Project Advancement
The freshly raised capital will primarily back the advancement of Andromeda’s High Purity Alumina (HPA) Project, particularly supporting the completion of a Pre-feasibility study (PFS). This phase is critical in refining the project's economic and technical parameters ahead of potential commercialisation. The remainder of the funds will cover general working capital needs and costs associated with the capital raise.
Andromeda’s HPA project has been progressing steadily, with recent pilot plant commissioning and purity milestones positioning the company to unlock value in specialty chemicals. The Pre-feasibility study will build on these developments and help define the next steps for the project’s path to production.
Shareholder Engagement and Market Impact
Shareholders received the new shares on 4 September 2026, with quotation on the ASX scheduled for 7 September. The company expressed gratitude for the strong participation in the SPP, which signals ongoing investor confidence in Andromeda’s strategy and project potential.
The issue price of $0.0059 per share reflects a modest discount typical of capital raises aimed at balancing shareholder value and market appetite. The use of placement capacity under ASX Listing Rule 7.1 allowed Andromeda to efficiently raise funds without the need for a lengthy shareholder approval process.
Bottom Line?
The successful capital raise strengthens Andromeda’s financial footing as it advances its HPA project through a key development milestone, though investors will watch closely for updates on the Pre-feasibility study outcomes and subsequent funding requirements.
Questions in the middle?
- How will the Pre-feasibility study findings influence Andromeda’s project timeline and capital needs?
- What impact will the new shares have on shareholder dilution and market liquidity?
- Could further capital raises be necessary to move beyond the Pre-feasibility stage?